ESG Report 2024

7.1.2 Quality Supervision Our core production philosophy is "Be a Quality Enterprise, Prosperous and Strong". Obtaining authoritative quality certification not only ensures the protection of customers’ health, but also strengthens customers’ trust and confidence in our products. Being the leading comprehensive pharmaceutical enterprises in China that has fully passed the GMP certification, the Group has always strictly complied with the relevant regulations and continuously met the requirements of the certification standards. During the Year, we successfully passed a number of quality certifications from authoritative domestic and international institutions. The Group has a total of seven major production sites, 57.1% of which have obtained GB/T 19001-2016/ISO 19001: 2015 quality management system certification, further consolidating our leading position in the industry. Throughout the year, the Group underwent a total of 25 inspections by external regulatory bodies, both domestic and overseas, covering more than 81 products, and all of the inspections were free from serious defects, which fully demonstrated our excellent performance in quality management. 36 Environmental, Social and Governance Report 2024 The United Laboratories International Holdings Limited Inspection of the Group by External Regulators during the Year GMP Compliance Status Zhuhai Company Successfully passed the eighth online GMP inspection by the Mexican COFEPRIS. Passed the Brazilian GMP inspection with “Zero Deficiency” Zhuhai United Bio-Pharmaceutical Co., Ltd. The Yeast Expression Subunit Vaccine production line is a GMP-qualifies production line. Inner Mongolia Company Successfully completed the first Korea GMP on-site certification. Obtained ampicillin production license and passed the GMP compliance inspection of tazobactam and ampicillin production lines. Others Amoxicillin Sodium Aseptic Drug obtained CEP certificate again. During the Year, Inner Mongolia Company successfully passed the GMP certification inspection by the Ministry of Food and Drug Safety (MFDS) of Korea, which was the first time for the company to receive on-site inspection by the Korean pharmaceutical officials. Korea is known for its strict drug regulation, and the inspection covered the production process of Amoxicillin API, quality control, material management, utility systems and personnel training. Through document review, on-site inspection and employee communication, the auditor fully evaluated the company's production environment and quality management system, and highly praised the company's GMP implementation status. This certification marks the international recognition of the company's quality management system and lays a solid foundation for the expansion of the international market. In the future, the company will continue to follow the international GMP standards and provide high quality products for global users. Inner Mongolia Company successfully completed the Korea GMP on-site certification